Related Experiment Video
Updated: Aug 11, 2026
11:06
GC-based Detection of Aldononitrile Acetate Derivatized Glucosamine and Muramic Acid for Microbial Residue Determination in Soil
Published on: May 19, 2012
Properties of amidinated glucagons
European Journal of Biochemistry
|October 1, 1980
Summary
Researchers modified porcine glucagon using alkyl imidates. One derivative, N epsilon-acetamidino-glucagon, maintained full biological potency, offering a new method for studying this peptide hormone.
Area of Science:
- Biochemistry
- Endocrinology
- Hormone Research
Background:
- Glucagon is a key peptide hormone regulating blood glucose levels.
- Understanding glucagon's structure-activity relationship is crucial for metabolic research.
- Chemical modification offers a route to probe hormone function.
Purpose of the Study:
- To synthesize and characterize novel porcine glucagon derivatives.
- To evaluate the biological activity and receptor binding of modified glucagons.
- To explore new methods for studying glucagon's function.
Main Methods:
- Reaction of porcine glucagon with various alkyl imidates.
- Purification of glucagon derivatives using ion-exchange chromatography.
- Assessment of adenylate cyclase activation and 125I-glucagon binding assays.
Main Results:
- N epsilon-acetamidino-glucagon exhibited biological potency and binding affinity comparable to native glucagon.
- N epsilon-4-hydroxyphenylamidinoglucagon required a twofold higher concentration for similar activity.
- Dual modification of alpha and epsilon-amino groups yielded agonists with anomalous chromatographic behavior.
Conclusions:
- Modification of the epsilon-amino group with specific alkyl imidates preserves glucagon's biological potency.
- Alkyl imidate modification provides a valuable approach for creating reporter-labeled glucagon derivatives.
- Further studies can utilize these potent derivatives to investigate glucagon's role in metabolic regulation.
More Related Videos
Related Concept Videos
01:16Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...